002390.KS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 08:30):

Handok Inc. operates as an integrated pharmaceutical company. The company provides ETC and OTC drugs, medical devices, and in-vitro diagnostics instruments and devices...

Stats
Dagens volum	24 812.00
Gjennomsnittsvolum	20 878.00
Markedsverdi	187.05B
EPS	KRW0 ( 2024-05-03 )
Neste inntjeningsdato	( KRW0 ) 2024-07-25
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW7.77 (0.06%)

Volum Korrelasjon

Lang: -0.07 (neutral)

Kort: 0.00 (neutral)

Signal:(57.706) Neutral

HANDOK Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

HANDOK Inc. Korrelasjon - Valuta/Råvare

-0.08
( neutral )

-0.34
( neutral )

-0.48
( neutral )

0.32
( neutral )

-0.25
( neutral )

HANDOK Inc. Økonomi

Annual	2023
Omsetning:	KRW522.74B
Bruttogevinst:	KRW151.37B (28.96 %)
EPS:	KRW-2 091.39

FY	2023
Omsetning:	KRW522.74B
Bruttogevinst:	KRW151.37B (28.96 %)
EPS:	KRW-2 091.39

FY	2022
Omsetning:	KRW543.76B
Bruttogevinst:	KRW173.71B (31.95 %)
EPS:	KRW775.88

FY	2021
Omsetning:	KRW517.64B
Bruttogevinst:	KRW167.55B (32.37 %)
EPS:	KRW239.28

Financial Reports:

No articles found.

HANDOK Inc.

Handok Inc. operates as an integrated pharmaceutical company. The company provides ETC and OTC drugs, medical devices, and in-vitro diagnostics instruments and devices. It focuses on various therapeutic areas, such as oncology, diabetes and metabolic disorders, CNS orphan diseases, eye disorders, and other disease areas. The company also offers healthcare products comprising food supplements under the NatureSet and Culturelle brands; food and beverages; and medical nutrition products. Handok Inc. has a strategic collaboration agreement with AUM Biosciences Pte. Ltd. and CMG Pharmaceutical Co. Ltd. for the development, manufacturing, and commercialization of CHC2014, a pan-TRK inhibitor for cancer treatment. The company was formerly known as Handok Pharmaceuticals Co., Ltd and changed its name to Handok Inc. in July 2013. Handok Inc. was founded in 1954 and is based in Seoul, South Korea.